Savient Pharma plans sale of up to 4.6M shares - Forbes

Savient Pharma plans sale of up to 4.6M shares Forbes Gout is a painful type of arthritis caused by excess uric acid crystallizing and building up around joints and tendons. The buildup causes inflammation. ... Best Pharmaceutical Stock Alert - Savient PharmaceuticalsTransWorldNews (press release) Savient To Offer 4 Million Shares To Pay For Krystexxa's FDA ProcessNASDAQ Options Update: Savient (SVNT) & IVX Volatility MonitorThe Options Insider Benzinga -PR Newswire (press release) -Washington Examiner all 51 news articles »

Pine bark extract holds promise (but the proof isn't all in) - Los Angeles Times

Pine bark extract holds promise (but the proof isn't all in) Los Angeles Times ... in 1820 and was approved by the Food and Drug Administration a century ago to treat the inflammation and pain associated with an acute gout attack. ...

US HOT STOCKS: 99 Cents Only Stores Slides In Late Trading - Wall Street Journal

US HOT STOCKS: 99 Cents Only Stores Slides In Late Trading Wall Street Journal ... -11.81%) plans to offer 4 million shares, with proceeds to go to its effort to win Food and Drug Administration approval for a chronic gout treatment. ... and more »

Manage gout through your diet - WFMJ

Manage gout through your diet WFMJ About 60 percent of people who have a gout attack will have another within 12 months. So, it's important to start treatment with the first attack. ... and more »